ulviprubart
Abcuro completes enrolment for phase 2/3 IBM treatment trial
June 26, 2024Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart
Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
November 14, 2026
Envirogen secures place on NHS Scotland reverse osmosis framework
November 13, 2026
